Latest Insights

Enveda Secures $150M Series D, Advances Lead Program & Adds Ex-Pfizer R&D Chief to Board

Founded in 2019 and based in Boulder, Colorado, Enveda has raised $150 million in a Series D financing round, enrolled the first patient in a Phase 1b trial for its …

Continue ›››

CHARM Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitors for AML

CHARM Therapeutics has secured $80 million in Series B financing to push its AI-designed menin inhibitor program for acute myeloid leukemia (AML) into clinical development, with trials expected to begin …

Continue ›››

Potential Breakthrough in Cell Reprogramming as OpenAI and Retro Biosciences Report 50x Pluripotency Marker Expression Gains

OpenAI and Retro Biosciences have released new findings from a joint effort in AI-driven protein engineering. Using GPT-4b micro, a biology-specialized variant of GPT-4o, the team designed two modified versions …

Continue ›››

Enveda Secures $150M Series D, Advances Lead Program & Adds Ex-Pfizer R&D Chief to Board

CHARM Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitors for AML

Potential Breakthrough in Cell Reprogramming as OpenAI and Retro Biosciences Report 50x Pluripotency Marker Expression Gains

Immunai Opens Free Single-Cell Sequencing Program for Academic Labs

KYORIN Pharmaceutical Adopts AI Drug Discovery Platform From Elix

Innovatrix and Opyl Partner to Launch AI-Driven Insurance for Clinical Trial Failure

How AI Is Transforming Medicinal Chemistry: From Discovery to Manufacturing

Ginkgo, Inductive Bio, and Tangible Scientific Connect AI Models with Automated Labs for Drug Discovery

Silicon Valley’s Molecular Devices Brings AI to Brain Organoid Culture

Owkin to Bring Agentic AI into Vienna’s Oncology Ecosystem

Generative AI Designs Novel Antibiotics Against MRSA and Drug-Resistant Gonorrhea

BioAge Labs Begins Phase 1 Trial of Oral NLRP3 Inhibitor for Obesity